Celgosivir (MBI 3253; MDL 28574; MX3253) is anα-glucosidase Iinhibitor; inhibits bovine viral diarrhoea virus (BVDV) with anIC₅₀of 1.27 μM inin vitroassay.

IC50: 1.27 μM (α-glucosidase I)^[1]

Celgosivir is more effective (IC₅₀=20 μM) than the parent molecule (IC₅₀=254 μM) at causing the accumulation of glucosylated oligosaccharides in HIV-infected cells by inhibition of glycoprotein processing. Celgosivir exhibits potent antiviral activity against HIV-1 with an IC₅₀of 2.0±2.3 μM^[1]. Bovine viral diarrhoea virus (BVDV) is a closely related virus of hepatitis C virus (HCV). Celgosivir inhibits BVDV with IC₅₀values of 16 and 47 μM in plaque assay and cytopathic effect assay, respectively^[2]. Celgosivir inhibits DENV2 replication with an EC₅₀of 0.2 μM. The EC₅₀values against DENV1, 3 and 4 are less than 0.7 μM^[3].

Celgosivir fully protects AG129 mice from lethal infection with a mouse adapted dengue virus at a dose of 50 mg/kg twice daily (BID) for 5 days and is effective even after 48 h delayed treatment. The protection by celgosivir is dose- and schedule-dependent and that a twice-a-day regimen of 50, 25 or 10 mg/kg is more protective than a single daily dose of 100 mg/kg. Pharmacokinetics studies of celgosivir in mice shows that it rapidly metabolizes to castanospermine^[4]. During primary infection with a mouse-adapted DENV strain S221, mice shows increased viremia on day 3, yet 80% survived day 10 with virus completely cleared by day 8^[3].

259.30

C₁₂H₂₁NO₅

121104-96-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.